Combined topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) major leads to reduction in both lesion size and systemic parasite burdens

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 6, 2009, Pages 1234-1240

  Aguiar, Marta Gontijo ^a,b   Silva, Diana Lara ^b   Nunan, Fernando Antônio ^b   Nunan, Elzíria Aguiar ^a   Fernandes, Ana Paula ^a   Ferreira, Lucas Antônio Miranda ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b CENTRO UNIVERSITÁRIO NEWTON PAIVA   (Brazil)

Author keywords

Animal model; Cutaneous leishmaniasis; Efficacy evaluation; Therapy

Indexed keywords

MILTEFOSINE; PAROMOMYCIN; PLACEBO; DRUG DERIVATIVE; PHOSPHORYLCHOLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROTOZOAL ACTIVITY; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DIFFUSION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; LEISHMANIA MAJOR; MONOTHERAPY; MOUSE; NONHUMAN; SKIN LEISHMANIASIS; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECT; ORAL DRUG ADMINISTRATION; PARASITOLOGY; PATHOLOGY; SKIN; SPLEEN; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ANIMALS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FEMALE; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; MICE; MICE, INBRED BALB C; PAROMOMYCIN; PHOSPHORYLCHOLINE; SKIN; SPLEEN; TREATMENT OUTCOME;

EID: 76249101213     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp365     Document Type: Article

References (30)

1. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 2004; 27: 305-18.
2. Schreifer A, Wilson ME, Carvalho EM. Recent developments leading toward a paradigm switch in the diagnostic and therapeutic approach to human leishmaniasis. Curr Opin Infect Dis 2008; 21: 483-8.
3. Grevelink SA, Lener EA. Leishmaniasis. J Am Acad Dermatol 1996; 34: 257-72.
4. Croft SL, Coombs GH. Leishmaniasis - current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol 2003; 19: 502-8.
5. Berman F. Clinical status of agents being developed for leishmaniasis. Expert Opin Investig Drugs 2005; 14: 1337-46.
6. Garnier T, Croft SL. Topical treatment for cutaneous leishmaniasis. Curr Opin Investig Drugs 2002; 3: 538-44.
7. El-on J, Haveley S, Grunwald MH et al. Topical treatment of old world cutaneous leishmaniasis caused by Leishmania major: a doubleblind control study. J Am Acad Dermatol 1992; 27: 227-31.
8. Berman JD. Human leishmaniasis: clinical, diagnostic and chemotherapeutic developments in the last 10 years. Clin Infect Dis 1997; 24: 684-703.
9. Soto J, Fuya P, Herrera R et al. Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimoniate as treatment for American cutaneous leishmaniasis: controlled study. Clin Infect Dis 1998; 26: 56-8.
10. Neal RA, Murphy AG, Olliaro P et al. Aminosidine ointments for the treatment of experimental cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1994; 88: 223-35.
11. Grogl M, Schuster BG, Ellis WY et al. Successful topical treatment of murine cutaneous leishmaniasis with a combination of paromomycin (aminosidine) and gentamicin. J Parasitol 1999; 85: 354-9.
12. Bryceson ADM, Murphy A, Moody AH. Treatment of 'Old World' cutaneous leishmaniasis with aminosidine ointment: results of an open study in London. Trans R Soc Trop Med Hyg 1994; 88: 226-8.
13. Soto JM, Toledo JT, Gutierrez P et al. Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): Phase 2 pilot study. Am J Trop Med Hyg 2002; 66: 147-51.
14. Gonçalves GS, Fernandes AP, Souza RCC et al. Activity of a paromomycin hydrophilic formulation for tropical treatment of infections by Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis. Acta Trop 2005; 93: 161-7.
15. Mussi SV, Fernandes AP, Ferreira LAM. Comparative study of the efficacy of formulations containing fluconazole or paromomycin for topical treatment of infections by Leishmania (Leishmania) major and Leishmania (Leishmania) amazonensis. Parasitol Res 2007; 100: 1221-6.
16. Santos AM, Noronha EF, Ferreira LA et al. Effect of a hydrophilic formulation of topical paromomycin on cutaneous leishmaniasis among patients with contraindications for treatment with pentavalent antimonials. Rev Soc Bras Med Trop 2008; 41: 444-8.
17. Soto J, Arana BA, Toledo J et al. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 2004; 38: 1266-72.
18. Soto J, Toledo J, Gutierrez P et al. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect Dis 2001; 33: E57-61.
19. Soto J, Rea J, Balderrama M et al. Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. Am J Trop Med Hyg 2008; 78: 210-1.
20. Schraner C, Hasse B, Hasse U et al. Successful treatment with miltefosine of disseminated cutaneous leishmaniasis in a severely immunocompromised patient infected with HIV-1. Clin Infect Dis 2005; 40: 122-4.
21. Seifert K, Croft SL. In vitro and in vivo interactions between miltefosine and other antileishmanial drugs. Antimicrob Agents Chemother 2006; 50: 73-9.
22. Titus RG, Marchand M, Boon T et al. A limiting dilution assay for quantifying Leishmania major in tissues of infected mice. Parasite Immunol 1985; 7: 545-55.
23. Ferreira LS, Ramaldes GA, Nunan EA et al. In vitro skin permeation and retention of paromomycin from liposomes for topical treatment of the cutaneous leishmaniasis. Drug Dev Ind Pharm 2004; 30: 289-96.
24. Kanyok TP, Killian AD, Rodvold KA et al. Pharmacokinetics of intramuscularly administered aminosidine in healthy subjects. Antimicrob Agents Chemother 1997; 41: 982-6.
25. Castro GA, Nascimento DS, Nunan EA et al. In vitro skin permeation of paromomycin from topical formulations across normal and stripped hairless mouse skin. STP Pharma Sci 2003; 13: 203-8.
26. Escobar P, Yardley V, Croft SL. Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice. Antimicrob Agents Chemother 2001; 45: 1872-5.
27. Neal RA, Allen S, McCoy N et al. The sensitivity of Leishmania species to aminosidine. J Antimicrob Chemother 1995; 35: 577-84.
28. Bryceson A. Current issues in the treatment of visceral leishmaniasis. Med Microbiol Immunol 2001; 190: 81-4.
29. Mirkovich AM, Galelli A, Allison AC et al. Increased myelopoiesis during Leishmania major infection in mice: generation of 'safe targets', a possible way to evade the effector immune mechanism. Clin Exp Immunol 1986; 64: 1-7.
30. 3 (edelfosine) and amphotericin B. Acta Trop 2002; 81: 151-7.